-
How to face losing loved ones to neurodegenerative disorders
24 Apr 2024 23:52 GMT
… example, with Charcot disease, or amyotrophic lateral sclerosis (ALS). The patient, when they …
-
Claremont 2024 commencement ceremonies — we list them all
24 Apr 2024 22:49 GMT
… even though John, who had amyotrophic lateral sclerosis (ALS), did not live to …
-
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
24 Apr 2024 20:05 GMT
… patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and non-alcoholic steatohepatitis …
-
SSDI Waiting Period: Does SSDI pay you for the 5 month waiting period?
24 Apr 2024 19:36 GMT
… individuals with disabilities stemming from amyotrophic lateral sclerosis (ALS) and approved for SSDI …
-
Alzheimer’s drug Leqembi moves forward, still in low gear
24 Apr 2024 19:21 GMT
… – Qalsody (tofersen) for SOD1-mutated amyotrophic lateral sclerosis (ALS) and Skyclarys (omaveloxolone) for … competition to its big multiple sclerosis franchise and spinal muscular atrophy …
-
Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds: Kevin Church, PhD
24 Apr 2024 17:09 GMT
… (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS). In the past years …
-
Biogen stock climbs on strong Alzheimer’s drug sales
24 Apr 2024 15:54 GMT
… few years, as its multiple sclerosis drugs — long the mainstay of … expand further into immunology — multiple sclerosis is a disease of the … treatments for other conditions, including amyotrophic lateral sclerosis, Parkinson’s disease, and Huntington …
-
Alzheimer’s trial doses patients with stem cell treatment directly to brain
24 Apr 2024 14:57 GMT
… RB-ADSC infused into the lateral ventricles of the brain in … disease, traumatic brain injury and amyotrophic lateral sclerosis.
Alzheimer’s disease is a …
-
Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc
24 Apr 2024 14:22 GMT
… celecoxib. The therapy, an investigational amyotrophic lateral sclerosis (ALS) agent, has been granted … . PrimeC, An Oral Candidate for Amyotrophic Lateral Sclerosis, Meets Primary Safety and Secondary …
-
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
24 Apr 2024 11:59 GMT
… 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS). Forward Looking Statements This …